The US Food & Drug Administration (FDA) has granted Emergency Use Authorisation (EUA) to United States-based Cepheid's Xpert Xpress SARS-CoV-2, a rapid molecular diagnostic test for qualitative detection of SARS-CoV-2, the virus causing COVID-19, it was reported on Saturday.
The test is intended to operate on any of the company's more than 23,000 automated GeneXpert Systems worldwide, with a detection time of around 45 minutes.
The company is to start shipping the test from next week.
AgNovos Healthcare Receives Breakthrough Designation for Spine Device
Oasmia forms global partnership with Elevar for commercialisation of Apealea
Jazz Pharmaceuticals files JZP-258 NDA with FDA for treatment of cataplexy and EDS
FDA Provides Emergency Use Authorization to PerkinElmer for COVID-19 Testing
Tanner Pharma Group Expands Leukine Emergency Access Programme
Nuclein to Expedite Commercialisation of Hand-Held PCR Test to Aid in COVID-19 Pandemic
Hackensack Meridian Health licenses rapid test for COVID-19 to T2 Biosystems